Neuromyelitis Optica clinical trials

The registry lists 178 studies for Neuromyelitis Optica across more than 10 countries. 78 are recruiting or about to start. 122 of them are mainly about Neuromyelitis Optica (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04.

Get an email when these change. Save the Neuromyelitis Optica studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 52
Recruiting: 50
Not yet recruiting: 24
Status unknown: 19
Active, not recruiting: 12
Terminated: 9

Phase

Phase 2: 42
Phase 1: 36
Phase 3: 25
Phase 4: 10
Early Phase 1: 7

Where

China: 72
United States: 52
France: 19
Italy: 18
Germany: 13
United Kingdom: 12

Who runs them

Tianjin Medical University General Hospital (15) · Alexion Pharmaceuticals, Inc. (9) · Tongji Hospital (7) · Hoffmann-La Roche (5) · Third Affiliated Hospital, Sun Yat-Sen University (5) · Xuanwu Hospital, Beijing (5) · Hospices Civils de Lyon (4) · Beijing Tiantan Hospital (4)

What is being tested here

Drugs under test in Neuromyelitis Optica studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Inebilizumab	2	1	4
Efgartigimod alfa	2	0	2
Tambotatug	2	1	2
Anti-CD20 Monoclonal Antibody B001	2	1	2
Eculizumab	1	4	8
Satralizumab	1	4	5
Ravulizumab	1	3	3
Azathioprine	1	2	3
Methylprednisolone	1	1	3
Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112	1	0	1

Drug classes tested here Antimetabolites 1 open · Tyrosine kinase inhibitors (TKIs) 4 · Alkylating agents 3

Coming up

11phase 3 studies under way

33studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD · Phase 3 · Alexion Pharmaceuticals, Inc.
Dec 2026Azathioprine in MOGAD · Phase 3 · Hospices Civils de Lyon
Dec 2026Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · Tianjin Medical University General Hospital
Mar 2027A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) · Phase 3 · Hoffmann-La Roche
Aug 2027Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD · Phase 3 · Tianjin Medical University General Hospital
Oct 2027A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) · Phase 3 · Shanghai Jiaolian Drug Research and Development Co., Ltd
Nov 2026Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases · Polina Stepensky
Nov 2026China National Registry of Neuro-Inflammatory Diseases · Beijing Tiantan Hospital
Dec 2026A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders · TG Therapeutics, Inc.
Dec 2026Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) · Shanghai Pharmaceuticals Holding Co., Ltd

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger. 11 (22%) take children under 18. 3 (6%) are for women only and 0 (0%) for men only; 9 (18%) take healthy volunteers.

Recruiting studies that take each age, of 50
Age	Women	Men
10	7 (14%)	6 (12%)
18	47 (94%)	45 (90%)
30	48 (96%)	45 (90%)
40	47 (94%)	44 (88%)
50	47 (94%)	44 (88%)
65	45 (90%)	43 (86%)
75	38 (76%)	36 (72%)
85	32 (64%)	30 (60%)

Across all 178 studies, recruiting or not: 43% stop at 75 or younger and 25% at 65; 23% take children; 3% are for women only and 0% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered1

Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients HealthOct 28, 2026NCT07902479

Studies

Recruiting first, then most recently updated. Showing 50 of 178. Browse all 178 → or search them.